참고문헌 (30)

1. 1 Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 264 22437870 

   상세보기

2. 2 Borghaei H Paz-Ares L Horn L Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015 373 1627 1639 26412456 

   상세보기

3. 3 Herbst RS Baas P Kim DW Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 2016 387 1540 1550 26712084 

4. 4 Gibney GT Weiner LM Atkins MB Predictive biomarkers for checkpoint inhibitor-based immunotherapy Lancet Oncol 2016 17 e542 e551 27924752 

   상세보기

5. 5 Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 2443 2454 22658127 

   상세보기

6. 6 Ock CY Keam B Kim S Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration Clin Cancer Res 2016 22 2261 2270 26819449 

   상세보기

7. 7 Rizvi NA Hellmann MD Snyder A Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 2015 348 124 128 25765070 

8. 8 Rooney MS Shukla SA Wu CJ Getz G Hacohen N Molecular and genetic properties of tumors associated with local immune cytolytic activity Cell 2015 160 48 61 25594174 

   상세보기

9. 9 Ayers M Lunceford J Nebozhyn M IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade J Clin Invest 2017 127 2930 2940 28650338 

   상세보기

10. 10 Ock CY Hwang JE Keam B Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers Nat Commun 2017 8 1050 29051489 

    상세보기

11. 11 Cho JH Sorensen SF Choi YL Programmed death ligand 1 expression in paired non-small cell lung cancer tumor samples Clin Lung Cancer 2017 18 e473 e479 28669849 

    상세보기

12. 12 Sheng J Fang W Yu J Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer Sci Rep 2016 6 20090 26822379 

    상세보기

13. 13 Herbst RS Baas P Perez-Gracia JL Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial Ann Oncol 2019 30 281 289 30657853 

    상세보기

14. 14 Eisenhauer EA Therasse P Bogaerts J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 228 247 19097774 

    상세보기

15. 15 Topalian SL Taube JM Anders RA Pardoll DM Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 2016 16 275 287 27079802 

    상세보기

16. 16 Zhang N Zeng Y Du W The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer Int J Oncol 2016 49 1360 1368 27499357 

    상세보기

17. 17 Ota K Azuma K Kawahara A Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer Clin Cancer Res 2015 21 4014 4021 26019170 

    상세보기

18. 18 Scheel AH Ansen S Schultheis AM PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations Oncoimmunology 2016 5 e1131379 27467949 

    상세보기

19. 19 Ock CY Kim S Keam B Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma Oncotarget 2017 8 97920 97927 29228662 

    상세보기

20. 20 Shin J Chung JH Kim SH Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer Cancer Res Treat 2019 51 1086 1097 30428640 

    상세보기

21. 21 Han JJ Kim DW Koh J Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer Clin Lung Cancer 2016 17 263 270 26707383 

22. 22 Illidge T Lipowska-Bhalla G Cheadle E Radiation therapy induces an adaptive upregulation of PD-L1 on tumor cells which may limit the efficacy of the anti-tumor immune response but can be circumvented by anti-PD-L1 Int J Radiat Oncol Biol Phys 2014 90 1 Suppl S776 

23. 23 Ilie M Long-Mira E Bence C Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies Ann Oncol 2016 27 147 153 26483045 

    상세보기

24. 24 Bigras G Mairs S Swanson PE Morel D Lai R Izevbaye I Small biopsies misclassify up to 35% of PD-L1 assessments in advanced lung non-small cell lung carcinomas Appl Immunohistochem Mol Morphol 2018 26 701 708 30095468 

    상세보기

25. 25 Kim H Kwon HJ Park SY Park E Chung JH PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study Oncotarget 2017 8 98524 98532 29228707 

    상세보기

26. 26 Zhou J Gong Z Jia Q Wu Y Yang ZZ Zhu B Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer Biochem Biophys Res Commun 2018 498 751 757 29526752 

    상세보기

27. 27 Kim S Koh J Kwon D Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas Eur J Cancer 2017 75 141 149 28222308 

    상세보기

28. 28 Hirsch FR McElhinny A Stanforth D PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project J Thorac Oncol 2017 12 208 222 27913228 

    상세보기

29. 29 Scheel AH Dietel M Heukamp LC Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas Mod Pathol 2016 29 1165 1172 27389313 

    상세보기

30. 30 Ratcliffe MJ Sharpe A Midha A Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer Clin Cancer Res 2017 23 3585 3591 28073845 

    상세보기